AGL 38.00 Decreased By ▼ -0.25 (-0.65%)
AIRLINK 136.45 Decreased By ▼ -2.52 (-1.81%)
BOP 5.44 Decreased By ▼ -0.01 (-0.18%)
CNERGY 3.80 Increased By ▲ 0.01 (0.26%)
DCL 7.50 Decreased By ▼ -0.07 (-0.92%)
DFML 45.41 Decreased By ▼ -0.74 (-1.6%)
DGKC 78.52 Increased By ▲ 0.41 (0.52%)
FCCL 28.89 Decreased By ▼ -0.21 (-0.72%)
FFBL 57.00 Decreased By ▼ -0.10 (-0.18%)
FFL 9.27 Increased By ▲ 0.57 (6.55%)
HUBC 96.80 Decreased By ▼ -5.02 (-4.93%)
HUMNL 13.40 Decreased By ▼ -0.85 (-5.96%)
KEL 3.77 Decreased By ▼ -0.05 (-1.31%)
KOSM 7.28 Decreased By ▼ -0.12 (-1.62%)
MLCF 37.80 Decreased By ▼ -0.55 (-1.43%)
NBP 67.50 Decreased By ▼ -2.00 (-2.88%)
OGDC 167.52 Decreased By ▼ -2.50 (-1.47%)
PAEL 25.10 Decreased By ▼ -0.55 (-2.14%)
PIBTL 6.70 Increased By ▲ 0.10 (1.52%)
PPL 131.50 Decreased By ▼ -2.08 (-1.56%)
PRL 26.40 Increased By ▲ 1.40 (5.6%)
PTC 15.10 Decreased By ▼ -0.44 (-2.83%)
SEARL 62.25 Decreased By ▼ -1.58 (-2.48%)
TELE 7.00 Increased By ▲ 0.05 (0.72%)
TOMCL 36.23 Decreased By ▼ -0.75 (-2.03%)
TPLP 7.88 Increased By ▲ 0.18 (2.34%)
TREET 14.00 Increased By ▲ 0.04 (0.29%)
TRG 44.55 Decreased By ▼ -0.42 (-0.93%)
UNITY 25.85 Increased By ▲ 0.45 (1.77%)
WTL 1.22 No Change ▼ 0.00 (0%)
BR100 9,143 Decreased By -61.6 (-0.67%)
BR30 27,326 Decreased By -391.2 (-1.41%)
KSE100 85,585 Decreased By -620.2 (-0.72%)
KSE30 26,984 Decreased By -252.2 (-0.93%)
World

Pfizer and Brazil regulator in talks to speed up emergency vaccine approval

  • The company said it continues to regularly submit trial data to Anvisa as part of the process of seeking full authorization for the vaccine.
Published December 31, 2020

BRASILIA: Pfizer Inc said in a statement on Wednesday that it had discussed in a meeting with Brazilian health regulator Anvisa how to speed up the process of applying for emergency use approval for its COVID-19 vaccine.

Pfizer said that, based on ongoing talks with the government and a planned meeting with Anvisa, it would consider whether to submit its vaccine for emergency use.

The company said it continues to regularly submit trial data to Anvisa as part of the process of seeking full authorization for the vaccine.

Comments

Comments are closed.